Detecting Parkinson's Disease in its early stages using EEG data presents a significant challenge. This paper introduces a novel approach, representing EEG data as a 15-variate series of bandpower and peak frequency values/coefficients. The hypothesis is that this representation captures essential information from the noisy EEG signal, improving disease detection. Statistical features extracted from this representation are utilised as input for interpretable machine learning models, specifically Decision Tree and AdaBoost classifiers. Our classification pipeline is deployed within our proposed framework which enables high-importance data types and brain regions for classification to be identified. Interestingly, our analysis reveals that while there is no significant regional importance, the N1 sleep data type exhibits statistically significant predictive power (p < 0.01) for early-stage Parkinson's Disease classification. AdaBoost classifiers trained on the N1 data type consistently outperform baseline models, achieving over 80% accuracy and recall. Our classification pipeline statistically significantly outperforms baseline models indicating that the model has acquired useful information. Paired with the interpretability (ability to view feature importance's) of our pipeline this enables us to generate meaningful insights into the classification of early stage Parkinson's with our N1 models. In Future, these models could be deployed in the real world - the results presented in this paper indicate that more than 3 in 4 early-stage Parkinson's cases would be captured with our pipeline.

Parkinson's disease (PD) is a slowly progressive, debilitating neurodegenerative disease which causes motor symptoms including gait dysfunction. Motor fluctuations are alterations between periods with a positive response to levodopa therapy ("on") and periods marked by re-emergency of PD symptoms ("off") as the response to medication wears off. These fluctuations often affect gait speed and they increase in their disabling impact as PD progresses. To improve the effectiveness of current indoor localisation methods, a transformer-based approach utilising dual modalities which provide complementary views of movement, Received Signal Strength Indicator (RSSI) and accelerometer data from wearable devices, is proposed. A sub-objective aims to evaluate whether indoor localisation, including its in-home gait speed features (i.e. the time taken to walk between rooms), could be used to evaluate motor fluctuations by detecting whether the person with PD is taking levodopa medications or withholding them. To properly evaluate our proposed method, we use a free-living dataset where the movements and mobility are greatly varied and unstructured as expected in real-world conditions. 24 participants lived in pairs (consisting of one person with PD, one control) for five days in a smart home with various sensors. Our evaluation on the resulting dataset demonstrates that our proposed network outperforms other methods for indoor localisation. The sub-objective evaluation shows that precise room-level localisation predictions, transformed into in-home gait speed features, produce accurate predictions on whether the PD participant is taking or withholding their medications.